PL3532497T3 - Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji - Google Patents

Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji

Info

Publication number
PL3532497T3
PL3532497T3 PL17865245.9T PL17865245T PL3532497T3 PL 3532497 T3 PL3532497 T3 PL 3532497T3 PL 17865245 T PL17865245 T PL 17865245T PL 3532497 T3 PL3532497 T3 PL 3532497T3
Authority
PL
Poland
Prior art keywords
hemaglutinating
reduce
hinge regions
immunoglobulin hinge
modified immunoglobulin
Prior art date
Application number
PL17865245.9T
Other languages
English (en)
Inventor
Jie Liu
Irving L. Weissman
Ravindra Majeti
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of PL3532497T3 publication Critical patent/PL3532497T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL17865245.9T 2016-10-26 2017-10-26 Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji PL3532497T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413018P 2016-10-26 2016-10-26
PCT/US2017/058569 WO2018081448A1 (en) 2016-10-26 2017-10-26 Modified immunoglobulin hinge regions to reduce hemagglutination

Publications (1)

Publication Number Publication Date
PL3532497T3 true PL3532497T3 (pl) 2024-11-04

Family

ID=62025462

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17865245.9T PL3532497T3 (pl) 2016-10-26 2017-10-26 Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji

Country Status (5)

Country Link
US (2) US10995152B2 (pl)
EP (1) EP3532497B1 (pl)
ES (1) ES2987333T3 (pl)
PL (1) PL3532497T3 (pl)
WO (1) WO2018081448A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3532497T3 (pl) * 2016-10-26 2024-11-04 The Board Of Trustees Of The Leland Stanford Junior University Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji
PL4177270T3 (pl) 2017-10-18 2024-11-18 Forty Seven, Inc. Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47
AU2021346729A1 (en) * 2020-09-28 2023-05-11 Shanghai Henlius Biologics Co., Ltd. Anti-cd47 antibodies and methods of use
CN119505008A (zh) * 2023-08-23 2025-02-25 菲鹏生物股份有限公司 免疫球蛋白及其多聚体

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
CN1018817B (zh) 1988-12-17 1992-10-28 中国石油化工总公司石油化工科学研究院 具有提高酸性的交联粘土的制备
WO2000068856A2 (en) 1999-05-11 2000-11-16 Webvan Group, Inc. Electronic commerce enabled delivery system and method
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US20090000224A1 (en) 2002-02-07 2009-01-01 Bay Industries, Inc. Pultruded door frame
GB0304823D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
US20060204496A1 (en) * 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
JP2005296412A (ja) 2004-04-13 2005-10-27 Olympus Corp 内視鏡治療装置
US8840933B2 (en) 2006-05-03 2014-09-23 Warsaw Orthopedic, Inc. Method of treating neuronal injury by administering magnesium chloride and PEG
US8330550B2 (en) 2006-06-23 2012-12-11 Rgb Systems, Inc. Method and apparatus for automatic compensation of video signal losses from transmission over conductors
CA2674382C (en) * 2007-01-03 2016-05-31 Morphotek, Inc. High affinity antibodies that neutralize staphylococcus enterotoxin b
US20110077383A1 (en) 2007-07-03 2011-03-31 Medimmune, Llc Hinge domain engineering
ES2796085T3 (es) 2008-01-15 2020-11-25 Univ Leland Stanford Junior Marcadores de células madre de leucemia mieloide aguda
JP5547656B2 (ja) 2008-01-15 2014-07-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７によって媒介される食作用を操作するための方法
GB2459509B (en) 2008-04-25 2011-05-11 Goodwin Plc An apparatus for casting and a method of casting
AR074438A1 (es) 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
SI2477648T1 (sl) 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
ES2609043T3 (es) 2009-11-30 2017-04-18 Janssen Biotech, Inc. Anticuerpos mutantes Fc con funciones de efecto abladas
US9276975B2 (en) 2010-03-24 2016-03-01 Thomson Licensing Method and apparatus for monitoring quality of service of network
JP2011216948A (ja) 2010-03-31 2011-10-27 Sony Corp カメラシステム、映像処理装置及びカメラ装置
CA3138956A1 (en) * 2010-05-14 2011-11-17 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
US9183590B2 (en) 2010-07-20 2015-11-10 Neopost Technologies System and method for managing postal accounting data using transient data collectors
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
EP2646007B1 (en) * 2010-12-02 2016-12-21 Neurotech USA, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
US20140038485A1 (en) 2011-04-07 2014-02-06 Cargill Incorporated Bio-based binders including carbohydrates and a pre-reacted product of an alcohol or polyol and a monomeric or polymeric polycarboxylic acid
KR101949293B1 (ko) 2011-05-05 2019-02-18 웰스태트 이뮤노테라퓨틱스, 엘엘씨 보체 인자 ｂ 유사체 및 그의 용도
AU2012274127B2 (en) * 2011-06-22 2017-06-22 F. Hoffmann-La Roche Ag Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes
AU2013209736C1 (en) * 2012-01-17 2017-12-14 The Board Of Trustees Of The Leland Stanford Junior University High affinity SIRP-alpha reagents
MY169341A (en) 2012-02-06 2019-03-21 Inhibrx Inc Cd47 antibodies and methods of use thereof
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
DE102012103533A1 (de) 2012-04-20 2013-10-24 Köra-Packmat Maschinenbau GmbH Vorrichtung zum Fördern eines Substrats und System zum Bedrucken eines Substrats
TWI641687B (zh) * 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
KR101910976B1 (ko) 2012-07-16 2018-10-23 삼성전자주식회사 그래핀을 이용한 전계효과 트랜지스터
DE102012213566A1 (de) 2012-08-01 2014-02-06 Robert Bosch Gmbh Verfahren zum Herstellen eines Bondpads zum Thermokompressionsbonden und Bondpad
IL293944A (en) 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
DK2906235T3 (en) 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
US9969789B2 (en) * 2012-12-17 2018-05-15 Trillium Therapeutics Inc. Treatment of CD47+ disease cells with SIRP alpha-Fc fusions
AR094147A1 (es) * 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft Polipeptidos de fusion con actividad de relaxina y sus usos
CA2900256C (en) 2013-02-05 2023-03-21 Kim J. HASENKRUG Cd47 targeted therapies for the treatment of infectious disease
EP2953643B1 (en) 2013-02-06 2023-02-22 Inhibrx, Inc. Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
JP6426693B2 (ja) * 2013-03-15 2018-11-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ｃｄ４７薬の処理上有効量を達成するための方法
ES2898627T3 (es) 2013-04-29 2022-03-08 Univ Leland Stanford Junior Uso de agentes anti-CD47 para mejorar la inmunización
WO2014186761A2 (en) 2013-05-17 2014-11-20 The Board Of Trustes Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-cd47 agent
HK1226084A1 (zh) * 2013-08-16 2017-09-22 Medimmune Limited 用於治疗糖尿病的gip和glp-1受体双重激动剂
EP3046627B1 (en) 2013-09-18 2019-10-23 The Board of Trustees of the Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
WO2015105995A2 (en) 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
CA2958898A1 (en) 2014-09-15 2016-03-24 The Board Of Trustees Of The Leland Stanford Junior University Targeting aneurysm disease by modulating phagocytosis pathways
CN104327187B (zh) 2014-10-11 2018-06-08 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
EP4019040A1 (en) 2015-01-21 2022-06-29 The Board of Trustees of the Leland Stanford Junior University Use of trl agonist and anti-cd47 agent to enhance phagocytosis of cancer cells
ES2838925T3 (es) 2015-02-27 2021-07-02 Univ Leland Stanford Junior Terapia de combinación para el tratamiento de la ateroesclerosis
US20180147257A1 (en) 2015-05-22 2018-05-31 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
SI3341015T2 (sl) 2015-08-26 2024-03-29 The Board Of Trustees Of The Leland Stanford, Junior University Izboljšana deplecija ciljanih celic z blokado CD47 in imunostimulatornim agonistom
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
WO2017100462A2 (en) 2015-12-11 2017-06-15 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with dual targeting of cd47 and egfr
US20190322741A1 (en) * 2016-06-07 2019-10-24 Macrogenics, Inc. Methods for the Use of CD32B x CD79B-Binding Molecules in the Treatment of Inflammatory Diseases and Disorders
PL3532497T3 (pl) * 2016-10-26 2024-11-04 The Board Of Trustees Of The Leland Stanford Junior University Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji

Also Published As

Publication number Publication date
US11760810B2 (en) 2023-09-19
EP3532497B1 (en) 2024-07-24
EP3532497A1 (en) 2019-09-04
WO2018081448A8 (en) 2024-01-04
US10995152B2 (en) 2021-05-04
ES2987333T3 (es) 2024-11-14
WO2018081448A1 (en) 2018-05-03
EP3532497C0 (en) 2024-07-24
EP3532497A4 (en) 2020-05-13
US20210253740A1 (en) 2021-08-19
US20200048369A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
IL263452A (en) Anti-ige antibodies
DK3143042T3 (da) Forbedrede variable immunoglobulindomæner
KR102355950B9 (ko) Tigit에 대한 항체
EP3417133A4 (en) HINGE
EP3498840A4 (en) ANTI-LAG-3 ANTIBODIES
EP3481869A4 (en) ANTI-CD73 ANTIBODIES
DK3411410T3 (da) Pd-1-antistoffer
DK3305680T3 (da) Lukke til beholdere
DK3089994T3 (da) Fabs-in-tandem-immunglobulin og anvendelser deraf
IL263329B (en) Lysine conjugated immunoglobulins
KR20180085002A (ko) 인간화된 항-cll-1 항체
IL270969A (en) Aggrecan binding immunoglobulins
EP3530967A4 (en) BIAXIAL HINGE
EP3406336A4 (en) NANO FOIL OF CORE CASE STRUCTURE TYPE
DK3125942T3 (da) Forstøvning af immunoglobulin
EP3507315A4 (en) MODIFIED POLYETHYLENE
DOS2016000090S (es) Cierre
EP3555382C0 (de) Rigolenhalbelement
PL3698279T3 (pl) Człon zamykający
EP3480482A4 (en) side flange
EP3471668C0 (en) CORK
DK3795591T5 (da) Cys80-konjugerede immunoglobuliner
PL3532497T3 (pl) Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji
DK3555383T3 (da) Drænkanal-halvelement
DK3456736T3 (da) Antistofvarianter